non-hodgkin

IRAK4-IN-7 (CA-4948) is a selective and potent IRAK4 kinase inhibitor with in vivo activity in a TLR4-induced cytokine release model.

BMS-986458 is a highly selective, orally active BCL6 PROTAC degrader. It specifically targets cereblon (CRBN) and the BCL6 N-terminal BTB domain to catalyze proximity-induced BCL6 degradation. BMS-986458 is applicable for research in B-cell non-Hodgkin lymphoma.

Mitoguazone (Methyl-GAG) is a selective S-adenosyl-methionine decarboxylase inhibitor that penetrates the blood-brain barrier and disrupts polyamine biosynthesis. Mitoguazone is a synthetic polycarbonyl derivative with anti-tumor activity that inhibits the integration of HIV DNA into cellular DNA in monocytes and macrophages, inducing apoptosis. Mitoguazone can be used to prevent acute leukemia, Hodgkin lymphoma and non-Hodgkin lymphoma.

Daunorubicin (Daunomycin) citrate, a potent anti-tumor anthracycline antibiotic, acts as a topoisomerase II inhibitor. It effectively inhibits DNA and RNA synthesis, diminishes cancer cell viability, and promotes apoptosis and necrosis. This cytotoxic compound is utilized in researching a range of cancers, such as leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, and Wilms' tumor, as well as infections [1] [2] [4] [5].

Mosunetuzumab (BCT-4465A) is a humanized antibody based on immunoglobulin G1 that targets CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used to study relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) and refractory follicular lymphoma.

Pinatuzumab is a humanised monoclonal antibody targeting CD22, commonly used to synthesise the ADC molecule Pinatuzumab vedotin, which is employed in the study of B-cell malignancies such as non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL).

Otlertuzumab (TRU-016) is a humanized monoclonal antibody that specifically targets the CD37 antigen, which is highly expressed on the surface of B-cells. this targeted mechanism of action supports its ongoing clinical investigation for the treatment of relapsed or refractory B-cell malignancies, including follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinaemia (WM).

Apoptosis Inducer 11 (compound 3u) promotes apoptosis via the mitochondrial pathway and elicits a G2 M block alongside a marked reduction in the S phase within non-Hodgkin lymphoma cell lines [1].

Bendamustine (SDX105) for the treatment of Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

Iladatuzumab vedotin (DCDS-0780A) is an ADC compound targeting CD79b, conjugated with the cytotoxic drug MMAE through a cleavable dipeptide linker mc-val-cit-PABC, used in the study of non-Hodgkin lymphoma.

Vorsetuzumab mafodotin, a humanized anti-CD70 monoclonal antibody, conjugates with monomethyl auristatin F (MMAF) through Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. This affinity allows targeting of various solid tumors and cancers such as renal cell carcinoma, pancreatic, ovarian, and lung cancers, alongside multiple myeloma and several forms of non-Hodgkin lymphoma, all of which express CD70.

Anti-CD22-NMS249 is an antibody-drug conjugate (ADC) that targets CD22, comprising the humanized anti-CD22 antibody Pinatuzumab, a cleavable linker (Mc-VC-PAB), and the effective payload of DNA topoisomerase II inhibitor PNU-159682. This compound is utilized in the study of non-Hodgkin lymphoma (NHL).

HX009 is a bispecific antibody that targets PD1 and CD47, though its binding to CD47 is attenuated. HX009 functions by blocking PD1/CD47 and can be utilized in research related to non-Hodgkin lymphoma (NHL).

RG-6333 is a bispecific agonist targeting CD19 and CD28. It specifically identifies and binds to the CD19 antigen present on the surface of malignant B cells, effectively targeting tumor cells. By engaging with CD28, RG-6333 activates T cells, overcoming activation barriers and boosting antitumor immunity. RG-6333 is applicable for research in relapsed/refractory non-Hodgkin lymphoma.

Obinutuzumab (Obinutuzumab/afutuzumab) GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.